OncoCyte Corporation (OCX)

Market Cap	46.30M
Revenue (ttm)	709,000
Net Income (ttm)	-43.61M
Shares Out	16.84M
EPS (ttm)	-4.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,347
Open	2.500
Previous Close	2.550
Day's Range	2.500 - 2.780
52-Week Range	2.285 - 4.305
Beta	1.00
Analysts	Buy
Price Target	4.42 (+60.73%)
Earnings Date	Nov 12, 2024

About OCX

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: OCX
• Website: https://www.oncocyte.com

Financial Performance

In 2023, OncoCyte's revenue was $1.50 million, an increase of 56.89% compared to the previous year's $958,000. Losses were -$28.72 million, -60.88% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.42, which is an increase of 60.73% from the latest price.

Price Target

$4.42

(60.73% upside)

Analyst Consensus: Buy